2024
Cost-effectiveness and health impact of screening and treatment of Mycobacterium tuberculosis infection among formerly incarcerated individuals in Brazil: a Markov modelling study
van Lieshout Titan A, Klaassen F, Pelissari D, de Barros Silva J, Alves K, Alves L, Sanchez M, Bartholomay P, Johansen F, Croda J, Andrews J, Castro M, Cohen T, Vuik C, Menzies N. Cost-effectiveness and health impact of screening and treatment of Mycobacterium tuberculosis infection among formerly incarcerated individuals in Brazil: a Markov modelling study. The Lancet Global Health 2024, 12: e1446-e1455. PMID: 39151980, PMCID: PMC11339731, DOI: 10.1016/s2214-109x(24)00221-3.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsTuberculosis preventive treatmentTuberculosis deathsHealth impactsImpact of screeningIntervention cost-effectivenessInfection screeningCost-effectiveNational Institutes of HealthHealth outcomesHealth gainsInstitutes of HealthQuantify health effectsTuberculosis casesCost-effectiveness ratioTreatment of Mycobacterium tuberculosis infectionPotential health impactsLife yearsGreater health benefitsTuberculosis preventionTarget populationMonths of isoniazidMarkov modelling studiesHealth statesHealthQuantifying gaps in the tuberculosis care cascade in Brazil: A mathematical model study using national program data
Emani S, Alves K, Alves L, da Silva D, Oliveira P, Castro M, Cohen T, de Macedo Couto R, Sanchez M, Menzies N. Quantifying gaps in the tuberculosis care cascade in Brazil: A mathematical model study using national program data. PLOS Medicine 2024, 21: e1004361. PMID: 38512968, PMCID: PMC10994550, DOI: 10.1371/journal.pmed.1004361.Peer-Reviewed Original ResearchDisability-adjusted life yearsLoss to follow-upTreatment loss to follow-upCare cascadeHealth lossDelay to diagnosisTB diseaseTB diagnosisReduce delays to diagnosisHuman immunodeficiency virusContribution of social factorsTotal health system costsCare cascade outcomesTB care cascadeMortality Information SystemBurden of TB diseaseHealth system costsLifetime health outcomesNotifiable Diseases Information SystemBurden of diseaseIncident TB casesState of residenceNational program dataFollow-upHealth outcomes
2023
Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis
Menzies N, Allwood B, Dean A, Dodd P, Houben R, James L, Knight G, Meghji J, Nguyen L, Rachow A, Schumacher S, Mirzayev F, Cohen T. Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis. Nature Communications 2023, 14: 6182. PMID: 37794037, PMCID: PMC10550952, DOI: 10.1038/s41467-023-41937-9.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsRifampicin-resistant tuberculosisRR-TBGlobal burdenSubstantial short-term morbidityRifampicin-susceptible tuberculosisShort-term morbidityOverall disease burdenLong-term health impactsPost-treatment careTB survivorsDisease burdenTreatment outcomesTuberculosis survivorsCase detectionLife yearsRifampicin resistanceTuberculosisHealth impactsBurdenHealth expenditureDiseaseSurvivorsMathematical modeling analysisFormer Soviet Union countries
2018
The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study
Yaesoubi R, Trotter C, Colijn C, Yaesoubi M, Colombini A, Resch S, Kristiansen PA, LaForce FM, Cohen T. The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study. PLOS Medicine 2018, 15: e1002495. PMID: 29364884, PMCID: PMC5783340, DOI: 10.1371/journal.pmed.1002495.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsMeningococcal casesConjugate vaccineMeningitis beltVaccination strategiesMeningococcal serogroupsStrain replacementNationwide immunization campaignPolyvalent meningococcal vaccineMeningococcal conjugate vaccineCurrent World Health OrganizationAfrican meningitis beltAlternative vaccination strategiesAlternative vaccination policiesWorld Health OrganizationMeningococcal transmissionReactive campaignsMeningococcal vaccineImmunization campaignVaccination policyPolyvalent vaccineMeningitis epidemicsReactive vaccinationVaccine policyVaccine price